# Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

> **NCT06906081** · PHASE2 · RECRUITING · sponsor: **Peter Rossing** · enrollment: 100 (estimated)

## Conditions studied

- Cardiovascular Autonomic Neuropathy
- Type 2 Diabetes
- Diabetic Neuropathies

## Interventions

- **DRUG:** Kerendia (Finerenone, BAY94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06906081
- **Lead sponsor:** Peter Rossing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906081, "Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06906081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*